Open an account

Medicus Pharma

MDCX · NASDAQ

$2.50−$0.12 (−4.58%)TodayMarket closed ·
Prev close $2.62

About MDCX

Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is headquartered in Conshohocken, Pennsylvania and currently employs 16 full-time employees. The company went IPO on 2023-10-11. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The company is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

Employees
16
Headquarters
Conshohocken, Pennsylvania
Listed
Oct 11, 2023
Sector
Health Care
Industry
Biotechnology
Website
medicuspharma.com

MDCX key statistics

Market cap
4.85M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
83.81K
Volume
84.17K
Open price
$2.60
High today
$2.61
Low today
$2.50
52 Week high
$139.00
52 Week low
$2.55

Medicus Pharma (MDCX) at a glance

As of Oct 23, 2026, Medicus Pharma (MDCX) shares are priced at $2.50, giving the company a market cap of 4.85M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.50 and $2.61. The current price is 0.0% above the day's low and 4.2% below its high.

Volume so far is 84.17K shares, in line with the average of 83.81K shares a day.

Over the past year Medicus Pharma has ranged from $2.55 to $139.00, and now sits 0% of the way up that range.

Medicus Pharma met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$10.50 per share against an estimate of -$6.50.

The average analyst price target is $207.82, 8213.0% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $207.82
Low
$15.15
Now
$2.50
High
$472.50

MDCX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 39.1% on average.

  1. Q3 FY24: reported -$0.846 per share against an estimate of -$0.3876
  2. Q4 FY24: reported -$0.18 per share against an estimate of -$0.2958
  3. Q1 FY25: reported -$0.42 per share against an estimate of -$0.238
  4. Q2 FY25: reported -$0.42 per share against an estimate of -$0.2618
  5. Q3 FY25: reported -$0.65 per share against an estimate of -$0.2958
  6. Q4 FY25: reported -$0.83 per share against an estimate of -$0.1564
  7. Q1 FY26: reported -$15.50 per share against an estimate of -$9.82
  8. Q2 FY26: reported -$10.50 per share against an estimate of -$6.50

MDCX news

  • Avi Kapoor

    Dow Falls Over 100 Points; US Initial Jobless Claims Decline

  • Press releaseGlobe Newswire

    Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value

  • Tanya Rawat

    Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why

  • Press releaseGlobe Newswire

    Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

  • Vandana Singh

    Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus

  • Press releaseGlobe Newswire

    Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

  • Press releaseGlobe Newswire

    Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

  • Press releaseGlobe Newswire

    Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company

Similar companies

Companies in the same industry as Medicus Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.